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ABSTRACT
Objective: To examine the short-term impact of quadrivalent
human papillomavirus (HPV) (types 6/11/16/18) recombi-
nant vaccination upon HPV disease-related health-care
resource utilization and costs among young women.
Methods: We analyzed data from a randomized clinical trial
comparing quadrivalent vaccination to placebo, among
women (N = 7861) primarily 16 to 23 years of age at enroll-
ment. HPV disease episodes, health-care resource utilization
and costs associated with cervical, vaginal, and vulvar pre-
cancers, and anogenital warts were analyzed over a period of
2.5 years among women, regardless of baseline HPV status.
Results: Overall, there was a 25.9% (P < 0.001) reduction in
total HPV disease-related health-care costs among women
receiving vaccine versus placebo (absolute reduction $3939
per 100 trial enrollees). We observed similar overall reduc-
tions in HPV-disease episodes and resource utilization. There
was a statistically signiﬁcant reduction in HPV 6/11-related
disease episode costs of 65.1% ($1837 per 100), and a reduc-
tion of 51.4% ($1781 per 100) in HPV 16/18-related episode
costs.
Conclusions: Quadrivalent HPV vaccination can reduce
HPV disease events, resource use and costs when adminis-
tered to a broad population of young women 16 to 23 years
of age. Prevention of HPV types 6 and 11 yielded similar
value in terms of HPV disease cost offsets, compared to
protection against HPV 16 and 18, during the years initially
after vaccination. Over the short-term, costs of vaccination
exceed cost offsets associated with prevention of HPV
disease; however, quadrivalent HPV vaccination has previ-
ously been shown to be cost-effective in the longer term,
when fully accounting for health beneﬁts and cost offsets.
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Introduction
Human papillomavirus (HPV) infections are the
primary cause of cervical [1], anal, penile, vaginal, and
vulvar cancers [2]; anogenital warts [3] and recurrent
respiratory papillomatoses [4,5] and also have been
observed among a fraction of head and neck cancers
[6]. HPV types 16 and 18 play a major role in the
development of anogenital cancers, while types 6 and
11 are observed in the vast majority of anogenital
warts and recurrent respiratory papillomatoses [7].
The incidence of these HPV-related diseases varies by
condition with, for instance, in the United States, an
estimated 11,150 women projected to have received a
diagnosis of cervical cancer in 2007, 3490 with vulvar
cancer [8], and approximately 500,000 men and
women with anogenital warts (Puneet K. Singhal, per-
sonal communication).
Clinical trials have recently demonstrated that a
quadrivalent human papillomavirus (types 6, 11, 16,
and 18) recombinant vaccine (Gardasil®, Merck &
Co. Inc., Whitehouse Station, NJ) provides 98% to
100% protection against incident cervical intraepithe-
lial neoplasia (CIN) grades 2/3 and anogenital warts
positive for the four targeted HPV types [9,10] with
sustained efﬁcacy through 5 years of trial follow-up
[11]. This quadrivalent vaccine has additionally
received approval for, and shown high efﬁcacy against,
vulvar and vaginal disease caused by HPV types 6, 11,
16, and 18 [12]. We have previously modeled the long-
term population health impact and cost-effectiveness
of quadrivalent HPV vaccination within the United
States [13] and Mexico [14]. In this article, we
examine the impact of quadrivalent human papilloma-
virus (types 6, 11, 16, and 18) recombinant vaccina-
tion (henceforth “quadrivalent vaccination”) upon
HPV disease-related health-care resource utilization
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and costs over 2.5 years, as observed among young
women primarily between 16 and 23 years of age,
enrolled in a multicenter phase III randomized clinical
trial.
Primary analyses describing vaccine prophylactic
efﬁcacy have focused upon women who were naive to
HPV 6, 11, 16, and 18 at baseline and assessed subse-
quent development of infection and disease caused by
these types [9–12,15–18]. The economic analyses pre-
sented here provide a distinct perspective in evaluating
health economic trends observed within the trial, and
experiences during the ﬁrst few years after vaccination,
of a broad group of young women, regardless of base-
line HPV status or infection type. Thus, in addition to
disease caused by incident HPV 6, 11, 16, and 18
infections, which quadrivalent vaccination has been
demonstrated to prevent [9–12,15–18], the analyses
also include evaluation of disease events caused by
prevalent HPV 6, 11, 16, and 18 infections present at
baseline (against which quadrivalent vaccination, as a
prophylactic intervention, has no impact), as well as
disease caused by both prevalent and newly acquired
infections with HPV types not targeted by the vaccine.
Methods
A full description of the quadrivalent vaccine phase III
clinical trial program has been reported elsewhere
[10,15,19]. We brieﬂy summarize here the study
aspects of principal relevance to the present economic
evaluation. General considerations for trial-based eco-
nomic evaluations have been previously reviewed
[20,21].
Clinical Trial Study Designs
The Females United To Unilaterally Reduce Endo/
Ectocervical Disease (FUTURE) I and II trials were
designed to evaluate the efﬁcacy and safety of
quadrivalent vaccination in reducing the incidence of
external genital warts, vulvar intraepithelial neoplasia
(VIN), vaginal intraepithelial neoplasia (VaIN), vulvar
cancer, vaginal cancer, cervical intraepithelial neopla-
sia (CIN), cervical adenocarcinoma in situ (AIS), and
cervical cancer compared to placebo. These multina-
tional double-blind randomized clinical trials enrolled
17,599 women, primarily 16 to 23 years of age.
At enrollment, women were healthy and with intact
uteri, nonpregnant, generally reported four or fewer
lifetime male sexual partners and did not report a prior
abnormal Pap test result, CIN diagnosis, or anogenital
warts. The three-series vaccination was administered
at day 1, month 2, and month 6 of the trial. After
enrollment, routine study visits were scheduled every 6
to 12 months, with liquid-based cytology (ThinPrep,
Cytyc, Boxborough, MA) and gynecologic examina-
tion of the external genitalia conducted at each visit.
Women with routine cytology of atypical squamous
cell-favors high-grade squamous intraepithelial lesion
(ASC-H), atypical glandular cell (AGC), or high-grade
squamous intraepithelial lesion (HSIL) were immedi-
ately referred for colposcopy, while referral algorithms
for atypical squamous cell-undetermined signiﬁcance
(ASC-US) and low-grade squamous intraepithelial
lesion (LSIL) Pap smears varied between the FUTURE
I and II studies.
Conﬁrmation of disease end points in the primary
per protocol analyses of clinical efﬁcacy [10,15,19]
was based on consensus histology as determined by an
expert pathology panel. For the health economic
analyses, end points were determined based on disease
histology as assessed by central pathology laborato-
ries, as these diagnostic results were used in directing
the clinical management of women within the trial,
and are most similar to how women are diagnosed in
clinical practice. Biopsy conﬁrmed CIN 2/3 was imme-
diately treated while CIN 1 was referred for treatment
if persistent. Accepted treatments for CIN included the
loop electrosurgical excision procedure (LEEP), laser
conization, and cold-knife conization. Genital warts
were treated via a modality as determined by the study
physician. The decision of whether and by what means
to treat VIN and VaIN was based on the discretion of
the physician.
Assessment of Health Economic End Points
We prespeciﬁed the time horizon for the health eco-
nomic analyses as through the rounded mean enrollee
follow-up time in the trial (2.5 years), with the eligible
study population consisting of women enrolled in the
FUTURE I and II trials for at least 2.5 years. All
women meeting this criteria receiving at least one
injection of vaccine or placebo were included in the
analysis, regardless of baseline HPV status. We found
no substantive differences in baseline characteristics or
treatment allocation between the full FUTURE I and II
populations (N = 17,599) and the cohort (N = 7861)
eligible for the health economic analyses (data not
shown). In the eligible cohort, 39.3% were enrolled in
FUTURE I and 60.7% in FUTURE II. Trial discontinu-
ation rates were very low, and similar between the
vaccine (4.1%) and placebo arms (3.7%).
Study physicians recorded resource utilization for
procedures used in HPV-disease diagnosis, treatment,
and follow-up. We excluded routine study procedures
indicated for all enrollees (e.g., cytology at scheduled
study visits) from tabulated procedures for health eco-
nomic analyses.
Episodes of care were derived for each HPV disease
end point. For genital warts, VIN and VaIN, episodes
began with the initial disease diagnosis on biopsy and
ended when at least 12 months had elapsed without a
genital wart, VIN, or VaIN-related health-care encoun-
ter. For CIN, episodes of care began with an initial
abnormal cytologic result and ended when at least
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12 months had elapsed without an abnormal cytologic
result (ASCUS) or other cervical HPV disease-related
procedure. We classiﬁed disease end points according
to the most severe histology observed during the
episode of care. HPV status for each episode of care
was assessed based on polymerase chain reaction
(PCR) typing of biopsy or surgical tissue specimens for
each disease end point and classiﬁed as HPV 6/11+
(i.e., 6+ and/or 11+), 16/18+, 6/11/16/18+, or 6/11/16/
18-. Methods used in the typing of HPV infections in
tissue specimens, and in cervical/anogenital swabs and
serology, for which data will be reported for all sub-
jects at trial enrollment, are described elsewhere
[10,11,15,22].
Consistent with prior quadrivalent vaccine trial-
based analyses of clinical efﬁcacy, cases of cervical HPV
disease detected solely based on colposcopic follow-up
for a ﬁnding of an external genital lesion within the trial
(in the absence of a prior abnormal Pap smear) were
excluded from the primary analyses. This exclusionwas
intended to reduce the possibility for ascertainment bias
if vaccination was found to be efﬁcacious in preventing
external genital lesions. We examined the impact of this
exclusion in a sensitivity analysis.
In the FUTURE II study, resource utilization data
associated with genital warts, VIN, and VaIN were
incomplete because these data were not routinely
reported for all patients. We therefore applied multiple
imputation methods for missing resource utilization
data because of these events using Imputation and
Variance Estimation Software (IVEware, Institute for
Social Research, University of Michigan, Ann Arbor,
MI). Using complete data on the number and type of
resource use for these events from FUTURE I, we
imputed the number of each type of procedure using a
sequential Poisson regression method [23]. Regression
covariates included study arm, age, region, number of
disease episodes for each end point testing positive for
speciﬁc HPV types (e.g., number of HPV 6/11+ genital
wart episodes), and number and type of other proce-
dures performed.
Health-care costs for procedures were not collected
within the trial. Costs were therefore assigned to the
mix of procedures observed at each trial visit using
reimbursed charge data for the relevant services from
the 2002 Medstat MarketScan® (Thomson Medstat,
Ann Arbor, MI) database, the most recent year avail-
able to us (Table 1). The MarketScan database reﬂects
health-care claims from more than four million pri-
vately insured US individuals. As was conducted for
resource utilization, regression-based multiple imputa-
tion methods were used to assign costs to genital wart,
VIN, and VaIN episodes for enrollees in FUTURE II.
Costs observed over the course of the trial were dis-
counted at a 3% annual rate and adjusted to 2006 US
dollars using the Medical Care component of the US
Consumer Price Index [24].
Statistical Analyses
Point estimates for study results were assessed as a rate
per 100 trial enrollees over 2.5 years of trial follow-up.
In estimating the treatment effect on the incidence of
disease episodes, we modeled data using negative bino-
mial regression, with treatment group as the indepen-
dent variable. P-values for differences between groups
in the incidence of events were estimated via a Wald
test statistic.
Mean differences in resource utilization rates and
health-care costs between the vaccine and placebo
groups were estimated using Poisson and linear regres-
sion methods, respectively, with treatment group as the
independent variable. Because the distributions of the
resource utilization and cost data were nonsymmetric,
we performed a bias-corrected accelerated (BCa) boot-
strap procedure [25] with 1000 replicates using S-Plus
software (Insightful, Seattle, WA) to estimate 95%
conﬁdence intervals (CI) and P-values for these end
points. The impact on overall results of varying
(50%) observed resource use and costs within the
trial population for each disease end point was exam-
ined in sensitivity analyses.
Results
Baseline characteristics of eligible subjects are reported
in Table 2 and were similar across trial arms.
Quadrivalent vaccination reduced the cumulative inci-
dence of all HPV disease episodes, regardless of causal
HPV type, by 22.2% (P < 0.01) as compared to
placebo over the 2.5-years follow-up period (Table 3).
The largest percentage reductions were observed for
genital warts, VaIN, and VIN (range 40–52%), com-
pared to ~15% for CIN. No cases of invasive cancer
were observed. Cumulative health-care resource utili-
zation (Table 4) was reduced by 20.3% (P < 0.001) or
Table 1 Costs assigned to health-care encounters with indi-
vidual procedures performed
Procedures Costs*
Pap test $84
HPV test $125
Vaginal biopsy $132
Colposcopy $140
Vulvar biopsy $168
Cryotherapy $176
Cervical biopsy $182
Chemical ablation $205
LEEP $453
Surgical excision $559
Laser ablation $738
*Costs are reported in 2002 US dollars and were derived from the Medstat Mar-
ketScan database from that year. Included is the costs are the payments from all
sources for the procedure itself along with those for professional and laboratory
(where applicable) fees associated with the encounter.Costs apply to instances where
a single procedure was performed at a given encounter.When multiple procedures
were performed at a single encounter, alternate costs were assigned from MarketScan
data based on the exact combination of services performed (data not shown).
HPV, human papillomavirus; LEEP, loop electrosurgical excision procedure.
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by 18.7 procedures per 100 trial enrollees (95% CI
8.0–29.1). Trends by disease type were similar to those
observed for incident episodes.
Quadrivalent vaccination reduced total HPV
disease-related health-care costs, regardless of causal
HPV type (Table 4) by 25.9% (P < 0.001) compared to
placebo (absolute reduction $3939 per 100 trial enroll-
ees, 95% CI $2047–$5572). Among those who were
HPV 6, 11, 16, and 18 naïve and had negative cervical
cytology at baseline, the percentage reduction in
Table 2 Baseline characteristics of eligible subjects
Baseline characteristic*
Quadrivalent HPV vaccine Placebo
N % N %
Number of enrollees 3937 50.1 3924 49.9
Region
Asia 82 2.1 84 2.1
Australia/New Zealand 76 1.9 72 1.8
Europe 2286 58.1 2265 57.7
Latin America 926 23.5 925 23.6
North America 567 14.4 578 14.7
Age†
16–18 1124 28.5 1120 28.5
19–21 1710 43.4 1725 44.0
22–23 1103 28.0 1079 27.5
Lifetime sexual partners
0 252 6.4 276 7.0
1–2 2140 54.4 2125 54.2
3–4 1467 37.3 1440 36.7
5 78 2.0 83 2.1
Age at ﬁrst sexual intercourse
Virgin (no sexual intercourse) 252 6.4 276 7.0
15 1036 26.3 1026 26.2
16–19 2355 59.8 2378 60.6
20 293 7.4 243 6.2
Current tobacco use 1112 28.2 1193 30.4
Ever pregnant 759 19.3 740 18.9
HPV status
HPV 6/11 seropositive 366 9.3 326 8.3
HPV 16/18 seropositive 525 13.3 510 13.0
HPV 6/11 PCR positive‡ 192 4.9 163 4.2
HPV 16/18 PCR positive‡ 456 11.7 426 11.0
Pap test result
Negative 3415 87.5 3406 88.0
ASC 171 4.4 184 4.8
AGC 4 0.1 2 0.1
LSIL 228 5.8 206 5.3
HSIL 27 0.7 17 0.4
Cancer 0 0.0 0 0.0
Unsatisfactory 58 1.5 56 1.5
HPV 6/11/16/18 positive§ or abnormal Pap test result 1209 31.3 1150 30.0
*Data were missing for the following variables (number of observations with missing data in placebo/quadrivalent HPV vaccine arms in parentheses): age at ﬁrst sexual intercourse
(1/1), HPV 6/11 serology (5/2), HPV 16/18 serology (5/2), HPV 6/11 swab PCR status (39/38), HPV 16/18 swab PCR status (38/40), Pap test result (53/34), HPV 6/11/16/18 status,
and Pap test result (96/76).
†One woman was age 15 at enrollment and included in the age 16 to 18 grouping and nine women were ages 24 to 26 and included in the age 22 to 23 grouping.
‡Women testing PCR positive on either an endo/ectocervical or labial/vulvar/perineal/perianal swab were considered positive for a given HPV type.
§Includes women in the placebo (N = 2) and quadrivalent HPV vaccine (N = 2) arms with an HPV 6-, 11-, 16-, or 18-positive result on PCR testing of an anogenital biopsy specimen
on day 1 of the trial.
AGC, atypical glandular cells;ASC, atypical squamous cells; HPV, human papillomavirus; LSIL, low-grade squamous intraepithelial lesion; HSIL, high-grade squamous intraepithelial
lesion; PCR, polymerase chain reaction.
Table 3 Incidence of events per100 trial enrollees
Quadrivalent HPV vaccine
cumulative incidence rate (N)
Placebo cumulative
incidence rate (N)
Difference cumulative
incidence rate (%) P-value
Anogenital warts 1.14 (45) 1.91 (75) -0.77 (-40.3%) <0.01
CIN 1 9.27 (365) 10.86 (426) -1.59 (-14.6%) 0.03
CIN 2/3 3.53 (139) 4.13 (162) -0.60 (-14.5%) 0.16
VaIN 0.79 (31) 1.33 (52) -0.54 (-40.6%) 0.03
VIN 0.89 (35) 1.86 (73) -0.97 (-52.2%) <0.01
All events 15.62 (615) 20.08 (788) -4.46 (-22.2%) <0.01
CI, conﬁdence interval; CIN, cervical intraepithelial neoplasia; HPV, human papillomavirus;VaIN, vaginal intraepithelial neoplasia;VIN, vulvar intraepithelial neoplasia.
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Table 4 Rates of health-care resource utilization and costs per 100 trial enrollees
Quadrivalent HPV vaccine Placebo Difference % 95% CI for difference
Health-care resource utilization by
disease end point
All eligible trial enrollees N = 3,937 N = 3,924
Anogenital warts
Colposcopies 0.5 1.1 -0.7 (-57.9%) (-1.2, -0.2)
Vulvar/Vaginal biopsies 0.5 1.1 -0.6 (-58.3%) (-1.1, -0.2)
Surgical excisions 0.7 1.1 -0.4 (-35.1%) (-0.9, 0.1)
Chemical ablations 0.2 0.7 -0.5 (-69.1%) (-1.2, -0.1)
Other wart procedures 0.6 1.1 -0.5 (-46.7%) (-1.1, 0.0)
All wart procedures 2.5 5.2 -2.7 (-52.4%) (-4.5, -1.0)
CIN 1
Follow-up cervical smears 4.0 4.1 -0.0 (-1.0%) (-1.1, 1.0)
HPV tests 5.4 6.1 -0.7 (-12.0%) (-2.1, 0.6)
Colposcopies 15.3 18.5 -3.2 (-17.4%) (-5.9, -0.5)
Cervical biopsies 12.9 15.8 -2.8 (-18.0%) (-5.0, -0.6)
ECCs 2.7 3.1 -0.4 (-11.9%) (-1.4, 0.6)
LEEPs 0.5 0.6 -0.1 (-21.1%) (-0.5, 0.2)
Other CIN 1 procedures 0.5 0.8 -0.2 (-30.2%) (-0.6, 0.1)
All CIN1 procedures 41.4 48.9 -7.6 (-15.4%) (-14.2, -0.4)
CIN 2/3
Follow-up cervical smears 1.9 2.2 -0.3 (-15.2%) (-1.1, 0.5)
HPV tests 1.4 2.0 -0.6 (-30.1%) (-1.3, 0.1)
Colposcopies 9.3 11.3 -1.9 (-17.0%) (-4.5, 0.0)
Cervical biopsies 7.8 9.4 -1.6 (-17.3%) (-4.0, 0.4)
ECCs 2.2 2.4 -0.3 (-10.8%) (-1.1, 0.7)
LEEPs 3.1 3.9 -0.8 (-20.4%) (-1.7, 0.0)
Other CIN 2/3 procedures 0.2 0.2 -0.1 (-33.6%) (-0.3, 0.1)
All CIN2/3 procedures 25.8 31.4 -5.6 (-17.9%) (-13.1, 1.3)
VaIN/VIN procedures 3.6 6.5 -2.8 (-43.9%) (-5.0, -1.0)
Total procedures 73.3 92.0 -18.7 (-20.3%) (-29.1, -8.0)
Health-care costs by disease end point
All eligible trial enrollees* N = 3,937 N = 3924
Anogenital warts $943 $1,790 -$848 (-47.3%) (-$1,504, -$221)
CIN 1 $5,741 $6,883 -$1,142 (-16.6%) (-$2,102, -$115)
CIN 2/3 $3,340 $4,068 -$728 (-17.9%) (-$1,728, $145)
VaIN/VIN $1,237 $2,459 -$1,221 (-49.7%) (-$2,016, -$560)
Total costs $11,261 $15,200 -$3,939 (-25.9%) (-$5,572, -$2,047)
Enrollees HPV 6/11/16/18 naive†
and with negative cervical
cytology at baseline
N = 2,600 N = 2,630
Anogenital warts $290 $1,318 -$1,028 (-78.0%) (-$1,605, -$504)
CIN 1 $3,304 $4,315 -$1,011 (-23.4%) (-$1,838, -$75)
CIN 2/3 $866 $1,879 -$1,012 (-53.9%) (-$1,706, -$404)
VaIN/VIN $792 $2,134 -$1,342 (-62.9%) (-$2,187, -$638)
Total costs $5,253 $9,646 -$4,393 (-45.5%) (-$6,109, -$2820)
Health-care costs by disease end point
and HPV type
All eligible trial enrollees N = 3,937 N = 3,924
Anogenital warts
HPV 6/11+ $596 $1,130 -$534 (-47.2%) (-$1,074, -$71)
HPV 16/18+ $0 $0 $0 (0.0%) —
HPV 6/11/16/18+‡ $596 $1,130 -$534 (-47.2%) (-$1,074, -$71)
HPV 6/11/16/18- $346 $660 -$314 (-47.6%) (-$691, $12)
CIN 1
HPV 6/11+ $129 $511 -$382 (-74.8%) (-$629, -$150)
HPV 16/18+ $470 $885 -$416 (-46.9%) (-$748, -$94)
HPV 6/11/16/18+‡ $599 $1,312 -$714 (-54.4%) (-$1,141, -$348)
HPV 6/11/16/18- $5,143 $5,571 -$428 (-7.7%) (-$1,367, $431)
CIN 2/3
HPV 6/11+ $72 $56 $16 (28.4%) (-$86, $121)
HPV 16/18+ $1,179 $2,181 -$1003 (-46.0%) (-$1,620, -$414)
HPV 6/11/16/18+‡ $1,251 $2,238 -$987 (-44.1%) (-$1,617, -$407)
HPV 6/11/16/18- $2,089 $1,830 $259 (14.1%) (-$406, $884)
VaIN/VIN
HPV 6/11+ $189 $1,126 -$938 (-83.3%) (-$1,399, -$577)
HPV 16/18+ $33 $395 -$363 (-91.7%) (-$778, -$171)
HPV 6/11/16/18+‡ $221 $1,442 -$1221 (-84.6%) (-$1,745, -$834)
HPV 6/11/16/18- $1,016 $1,016 -$0 (-0.0%) (-$546, $591)
Total costs
HPV 6/11+ $986 $2,823 -$1837 (-65.1%) (-$2,689, -$1,107)
HPV 16/18+ $1,681 $3,462 -$1781 (-51.4%) (-$2,556, -$1,038)
HPV 6/11/16/18+‡ $2,667 $6,122 -$3455 (-56.4%) (-$4,529, -$2,302)
HPV 6/11/16/18- $8,594 $9,078 -$484 (-5.3%) (-$1,864, $818)
*All enrollees with at least one vaccine or placebo injection.
†HPV 6/11/16/18 negative on baseline serology and genital swab/biopsy polymerase chain reaction (PCR) testing.
‡Costs for HPV 6/11/16/18+ episodes may be less than the sum of those observed for HPV 6/11+ and HPV 16/18+ episodes because of the presence of both HPV 6/11 and HPV 16/18 in lesions.
CI, conﬁdence interval; CIN, cervical intraepithelial neoplasia; ECCs, endocervical curettages; HPV, human papillomavirus; LEEPs, loop electrosurgical excision procedures;VaIN, vaginal intraepithelial neoplasia;
VIN, vulvar intraepithelial neoplasia.
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health-care costs was 45.5%. When analyzed by HPV
type, for the full eligible population, there were statis-
tically signiﬁcant reductions in HPV 6- or 11-related
disease episode costs of 65.1% (absolute reduction of
$1837 per 100 trial enrollees), and in HPV 16- or
18-related episode costs of 51.4% (absolute reduction
of $1781 per 100 trial enrollees) (Table 4). Slight
reductions in costs associated with disease episodes
lacking evidence of HPV 6/11/16/18 infection were
also seen (5.3%) with quadrivalent vaccination;
however, the differential was not statistically signiﬁ-
cant (reduction 95% CI -9.0–20.5%).
Total cost reductions per 100 enrollees associated
with all disease end points during months 1 to 12 of
the trial were 12.7% (95% CI -5.1–31.5), compared
to 27.7% (95% CI 14.3–40.5) over months 13 to 24,
and 34.5% (95% CI 14.3–40.5) over months 25 to 30
(95% CI 16.8–55.1). Among women who were virgins
at baseline, total HPV disease costs were reduced by
20.7% (95% CI -64.0–87.2) with vaccination, com-
pared to 29.4% (95% CI 13.2–47.0) among women
with one to two lifetime male partners and 18.4%
(95% CI 2.7–35.3) among those with three or more
partners. A sensitivity analysis allowing for the inclu-
sion of cervical HPV disease end points detected solely
based on colposcopic follow-up of external genital
lesions yielded negligible differences in percentage
(26.0%) and absolute ($3973 per 100 trial enrollees)
reductions in total HPV disease health-care costs in
comparison to the primary analyses.
The impact of varying (50%) rates of usage of
health-care resources (Fig. 1) and total costs (Fig. 2)
for each disease end point within the primary analyses
was examined in sensitivity analyses. Overall esti-
mated percentage reductions in resource utilization
rates and costs (quadrivalent HPV vaccine—placebo)
were modestly impacted by changes in resource use
rates (range 19.3–22.1%) or costs (range 23.8–28.6%)
associated with any single end point. When estimated
as absolute reductions, these ranges widened slightly
for both resource utilization (range 15.0–22.5 per 100;
mean 19.3 per 100) and health-care costs (range
$3328–$4550 per 100; mean $3939 per 100).
Conclusions
This article has reported the ﬁrst trial-based economic
evaluation of an HPV vaccine. Quadrivalent HPV vac-
cination was shown to signiﬁcantly reduce overall
disease events, health-care resource utilization, and
costs, within a 2.5 years time horizon, inclusive of data
for events caused by any HPV type and prevalent HPV
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Figure 1 Percentage difference in resource utilization rates per 100 trial enrollees ([placebo - quadrivalent HPV vaccine] / placebo) with procedure rates
of 50% for a given HPV disease end point.The impact of varying the rate of procedures performed for each disease end point and all end points upon
the overall estimated percentage reduction in HPV disease procedures per 100 enrollees (horizontal axis) is shown by the black bars.The vertical line
depicts the percentage reduction in procedure rates observed in the primary analysis (20.3%) as reported in Table 4.
0.0% 10.0% 20.0% 30.0%
CIN 1
VaIN/VIN
Genital Warts
CIN 2/3
Figure 2 Overall percentage reduction in health-care costs per 100 trial enrollees ([placebo - quadrivalent HPV vaccine] / placebo) with costs of 50%
for a given HPV disease end point.The impact of varying the costs associated with each disease end point upon the overall estimated percentage reduction
in HPV disease costs per 100 enrollees (horizontal axis) is shown by the black bars.The vertical line depicts the percentage difference in costs observed
in the primary analysis (25.9%) as reported in Table 4.
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infections at baseline. We believe the ﬁndings of this
study to be noteworthy in at least three respects.
First, it was demonstrated that quadrivalent vacci-
nation can yield important health and economic ben-
eﬁts, even among women who have generally already
initiated sexual activity. For instance, in spite of the
reservoir of prevalent HPV disease at baseline, it is
noteworthy that even over the short-term period
(2.5 years) evaluated in this study, vaccination reduced
HPV 6-, 11-, 16-, and 18-related costs by a substantial
margin (56%), as well as disease costs because of any
HPV type (26%). Previous trial-based analyses in the
clinical literature have focused on the prophylactic
efﬁcacy of HPV vaccines against infection/disease
caused by targeted HPV types, among women naïve to
those types at baseline, as a primary end point
[9–12,15,18,26,27]. This perspective has been particu-
larly useful for simulating the status of women before
the onset of sexual activity and HPV infection expo-
sure, such as among early adolescents receiving vacci-
nation. Prophylactic efﬁcacy against HPV 6, 11, 16,
and 18 infection and disease in these trial subpopula-
tions have been found to be very high (90–100%). The
quadrivalent HPV vaccine has been approved for use
among older adolescents and young women (up to age
26) in many countries, for females who did not receive
the vaccine during early adolescence. Although the
efﬁcacy of vaccination among these females is expected
to be lower, given the greater potential for prior expo-
sure to one or more vaccine HPV types, ﬁndings from
this study provide empirical support for the beneﬁts of
catch-up vaccination policies in these age groups.
Second, the absolute vaccine cost offsets attribut-
able to HPV 6- or 11-related disease were found to be
similar to those for HPV 16- or 18-related disease.
These data highlight the important short-term health
and economic beneﬁts of preventing HPV 6- and
11-related external genital lesions and CIN 1, in addi-
tion to preventing HPV 16- and 18-related disease.
Though nonmalignant, the most common of these
external genital lesions, anogenital warts, can have a
major negative psychosocial impact [28] and treat-
ments often require multiple patient visits with poten-
tially painful therapies involving genital burning,
freezing, or surgical excision [29,30].
Third, as an increasing fraction of prevalent disease
was cleared out over the course of the trial, both
absolute and percentage annualized HPV disease-
related cost reductions were observed to increase over
time, nearly tripling between year 1 and the start of
year 3 of the trial. Thus, the relative beneﬁts of
quadrivalent vaccination among women vaccinated
between the ages of 16 and 23 are likely to increase
rather than be static over time. As a further example of
this, the reductions in CIN 2/3 incidence (P = 0.16),
resource use (95% CI -13.1–1.3), and costs (95% CI
-$1728–$145) reported in this article did not achieve
statistical signiﬁcance within the rounded mean trial
follow-up time prespeciﬁed for our analyses
(2.5 years); likely because of a lack of statistical power
for evaluating reductions of these magnitudes. Never-
theless, a recent analysis of the clinical efﬁcacy of
quadrivalent HPV vaccination, with data reported for
all trial enrollees, including that occurring beyond our
rounded mean trial follow-up time, found a statisti-
cally signiﬁcant reduction in CIN 2/3 lesions, slightly
greater than that reported here (18% vs. 14.5%) [9].
During the analysis period, percentage reductions in
disease events, health-care resource use, and costs were
observed to be substantially larger for anogenital
warts, VaIN, and VIN, than for CIN. This ﬁnding may
relate to three factors. First, CIN 1 lesions, which
accounted for more than half of all disease episodes
observed in both the placebo and vaccine arms, have
been found to contain the HPV types targeted by
quadrivalent vaccination (types 6, 11, 16, and 18) in
lesser proportion (~25%) [31] than external genital
lesions, such as condyloma acuminata (>90%) [3,32].
Second, although the proportion of CIN 2/3 lesions
estimated to be caused by these four HPV types
(~60%) is higher than for CIN 1 [31], CIN 2/3 lesions
appear to take longer to develop and/or be diagnosed
after incident HPV infection than anogenital warts.
For instance, a recent study observed a median time to
the diagnosis of CIN 2/3 after incident HPV 16 or 18
infections of 14.1 months, compared to 2.9 months
for anogenital warts after incident HPV 6 or 11 infec-
tions [33]. Thus, it is likely that, compared to anogeni-
tal warts, a relatively greater fraction of all CIN 2/3
cases observed in the trial reﬂected either CIN 2/3
disease prevalent before vaccination, or disease result-
ing from prevalent HPV infection at baseline (as
opposed to disease resulting from incident HPV infec-
tions after vaccination). Hence, a smaller proportion
of CIN 2/3 cases may have been prevented given that
the vaccine has demonstrated prophylactic, but not
therapeutic efﬁcacy against HPV 6, 11, 16, and 18
infection and disease [11].
Third, while women may visually observe anogeni-
tal warts and VIN and seek treatment, CIN is typically
diagnosed upon follow-up for an abnormal Pap smear
result. It is therefore plausible that within the age
group (primarily 16–23) enrolled in the trial, women
with prior genital warts and VIN would have been
more likely to have been diagnosed and treated for
their condition, and been ineligible for inclusion within
the trial, whereas those with a prior CIN lesion may
have been more likely to have been enrolled, given that
Pap screening before this age range is sporadic or
nonexistent in most of the countries enrolling women
[34–36].
One of the strengths of this analysis is its internal
validity, with rigorous disease ascertainment and HPV
typing, and randomized double-blind evaluation of
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vaccine efﬁcacy. Nevertheless, several issues are worth
noting with respect to external generalizability.
First, women included in the analysis generally had
four or fewer lifetime sexual partners. Given the mul-
tinational composition of the trial population, it is
difﬁcult to generalize results to any speciﬁc geographic
setting. Nevertheless, with nearly 60% of enrollees
drawn from Europe, some general insights can be
acquired from comparing the sexual practices of the
trial population to those of the general population of
young women residing within this region in the United
Kingdom (UK). From a nationally representative
survey in the UK, an estimated 17.7% of females ages
16 to 24 are virgins, compared to 46.2% with one to
four lifetime male sexual partners and 36.1% with ﬁve
or more partners [37]. The trial population in this
analysis was comprised of comparatively fewer virgins
(6.7%) and women with ﬁve or more lifetime male
partners (2.0%). Thus, with respect to the UK and
countries with similar sexual practices, the trial popu-
lation may be most representative of the relatively
largest fraction of women with moderate levels of
prior sexual activity, while under-representing those at
the highest and lowest levels. Examination of baseline
HPV 16/18 seropositivity rates suggests that the trial
population may have had greater prior exposure to
these types than in population-based samples of
roughly similar age in Spain and Taiwan, but lower
than in Costa Rica [38–40].
Second, women in the trial underwent gynecologic
evaluation more frequently (every 6–12 months) than
most women in general clinical practice [35,36,41].
This frequent evaluation was undertaken to more com-
prehensively ascertain disease end points within the
trial. As a result, the incidence of HPV disease end
points and related health-care costs, especially those
which may only be detected as a result of cytologic
diagnosis or physician examination, may be consider-
ably higher as observed within the trial than in many
practice settings.
The annual incidence of CIN episodes (any grade)
observed within the trial placebo arm was 6.0 per 100.
For comparison, a retrospective population-based
study conducted within a large US health plan reported
a ﬁgure of approximately 0.6 per 100, among women
ages 15 to 24 [42]. Just more than 30% of women age
15 to 24 in that population underwent routine Pap
screening within a given year, with lower annual
screening rates reported within most other countries
[35,36,41]. The annual incidence of anogenital wart
episodes within the trial placebo arm was 0.8 per 100.
In the UK population, an annual incidence of genital
warts of 0.7 per 100 has been reported among women
age 16 to 24, based on data from genitourinary medi-
cine clinics [43]. An incidence of 1.3 per 100 women
age 15 to 24 has been observed within Borås, Sweden
[44]. Thus, while the incidence of CIN diagnosed
within the trial may be substantially higher than in
most population settings, the observed incidence of
genital warts may be fairly similar.
The relatively high diagnosis rates for CIN are likely
related to the frequent cervical screening intervals fol-
lowed within the trial, resulting in the diagnosis of
CIN lesions that otherwise may have spontaneously
regressed [45] or remained undetected until later in the
general population. In contrast, given that anogenital
warts may be visible to women and/or their partners,
prompting patients to seek treatment independent of
physician examination and screening, diagnosis rates
between the trial and population settings could be
expected to be more similar. VIN lesions may be symp-
tomatic and macroscopically visible to patients, while
VaIN is typically diagnosed upon screening and/or
physician examination.
Based on these comparisons, caution should be
exercised in generalizing results reported for absolute
reductions in disease episodes, resource use, and costs.
In particular, absolute reductions could be expected to
be smaller in settings where HPV disease is diagnosed
and managed less aggressively than within the trial or
where unit costs for managing disease are lower. Also,
percentage reductions in these outcomes, observed
across all HPV disease end points, are inﬂuenced by
the relative mix of CIN versus anogenital wart, VIN,
and VaIN cases detected. As a result, a higher effec-
tiveness in preventing all of these HPV disease end
points within 2.5 years after vaccination might be
expected within clinical practice, as CIN, for which the
lowest trial episode reductions were observed, would
be expected to be considerably less common, as com-
pared to anogenital warts and VIN, than observed
within the trial. For instance, a 90% reduction in the
observed rate of CIN and VaIN events within both trial
arms would have resulted in a reduction in disease
episodes of 37.3% (as compared to the observed
reduction of 22.2%). Nevertheless, as reported in the
sensitivity analyses, varying resource use rates or costs
associated with individual HPV disease events by
50% had a more modest impact on overall percent-
age reductions in resource use and costs. Percentage
reductions in HPV disease episodes, resource utiliza-
tion, and costs observed for speciﬁc disease end points
(e.g., for CIN), and as related to disease episodes asso-
ciated with speciﬁc HPV types (e.g., HPV 6/11+ epi-
sodes), would be expected to have greater external
generalizability.
Third, although FUTURE I and II were multina-
tional trials, to provide a common and practical metric
for valuing resource utilization, all costs were assigned
in US dollars. Costs of health-care services do vary
from country to country; however, the impact of which
could at least be partially explored through the appli-
cation of country-speciﬁc costs to resource use data
reported in Table 4.
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Finally, this analysis has focused on the short-term
(2.5 years) health economic impact of quadrivalent
HPV vaccination upon HPV disease. As a result, the
vast majority of beneﬁts of vaccination in preventing
the HPV disease end points examined, as well as cer-
vical, vaginal, and vulvar cancers, which typically
take many years to develop [46], are not included
within the time frame of the analysis. We also have
not included the costs of quadrivalent HPV vaccina-
tion (acquisition cost $360 per three-dose series or
$36,000 per 100 trial enrollees); however, over the
short-term, the costs of vaccination clearly exceed the
cost offsets associated with the prevention of HPV
disease. Over the longer term, economic modeling
can allow for both the full impact of the costs and
health beneﬁts of vaccination to be evaluated. We
recently showed quadrivalent vaccination to be well
within the range of cost-effectiveness of other cur-
rently accepted health-care practices when adminis-
tered among young US women 12 to 24 years of age
(similar to the current US indication for the vaccine)
as well as among women 18 to 24 years of age
(similar to the baseline age range of women in this
study) [13].
Studies are currently in development to monitor
the health impact of quadrivalent HPV vaccination in
various populations over the longer term [47] and
economic outcomes may also be examined as data
become available. Population-based health economic
studies will be inclusive of both the direct beneﬁts of
quadrivalent HPV vaccination to vaccinees as well as
indirect beneﬁts resulting from herd immunity. The
current analysis represents a ﬁrst step in this direc-
tion, evaluating the direct short-term health economic
beneﬁts of quadrivalent HPV vaccination among
young women as observed within vaccine phase III
clinical trials. Results suggest that in settings where
quadrivalent HPV vaccination is implemented among
older adolescents and young women, signiﬁcant
reductions in HPV disease episodes, resource use, and
costs can be expected over the short-term among
these individuals. The initial positive public health
impact is likely to be most apparent for anogenital
warts. Trends from this study and recent HPV
vaccine modeling work for the general population
suggest an increasing beneﬁt of vaccination over time
[13,48]. Because there are additional cervical cancer-
causing HPV types not currently covered by the
quadrivalent vaccine [49], vaccinated women should
continue to receive regular cervical screening exams
per local guidelines [50].
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